Publication: 2149

A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
      QxMD      Google Scholar   
Citation:
Neuro Oncol vol 17 (9) 1261-9
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Long-Term-Followup
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
5
Parents:
77   78   364   514  
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, CA33601, CA-37404, UL1 TR000135, U10 CA180821, K12 CA090628, CA-35103, CA-25224, CA-108961, P30 CA015083, U10 CA180882, CA-165962, CA31946, P50 CA165962, CA-35267  
Corr. Author:
 
Authors:
                               
Networks:
LAPS-MA036, LAPS-MN026, MN017, SANFORD, VA009   
Study
NCCTG-N057K
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1,2
Keywords:
everolimus, FLT-PET, glioblastoma, mTOR